FDA Inspection
Wuhan Biocause Pharmaceutical Development Co., Ltd.Wuhan Biocause Pharmaceutical Development Co., Ltd. – FDA Inspection, Mar 14, 2025
Record Details
This FDA Inspection record concerns Wuhan Biocause Pharmaceutical Development Co., Ltd., with an inspection on March 14, 2025, issued by the Office of Inspections and Investigations, covering human drugs.
- Inspection Date
- March 14, 2025
- Product Type
- Human Drugs
View Company Profile
ID · cf0802f0-fbd5-4ef6-8a2f-51da576523d8
Inspection Facts
- Inspection number
- 1267912
- FDA center
- Human Drugs
- Outcome
- Form 483 issued
Other FDA inspections of Wuhan Biocause Pharmaceutical Development Co., Ltd.
4| Date | Classification | Office | Project area |
|---|---|---|---|
| August 24, 2018 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| July 22, 2016 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| February 28, 2014 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| July 23, 2010 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
Other documents for Wuhan Biocause Pharmaceutical Development Co., Ltd.
- FDA Inspection 1069379 - 2018-08-24
- FDA Inspection 982641 - 2016-07-22
- FDA Inspection 873586 - 2014-02-28
- FDA Inspection 680329 - 2010-07-23
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.